It refers to nanoparticles composed of a basic hydrate acid and a therapeutic agent (1 - (4 - [4 - (dimethylamine) piperidin-1-il] carbonil) - 3 - [4 - (4,6-dimorfolin-4-il-1,3,5-triazin-2-il) phenyl] urea,Or acceptable salts and polymers on drugs Other aspects include the development and use of nanoparticles. 1. Characteristic 1: a therapeutic nanoparticle, including: about 0.05-30% of macrochannel acid by weight； about 0.2-25% of therapeutic agent by weight； in the primary therapeutic agent, pk8336 is at least stronger than 1.0 pk833636； 1. Pk833636 hydrate；And about 50-99.75% by weight from a polyphosphate (lactate) - polyglycol (ethanol) or a polyphosphate (lactate Co glicolic) - polyglycol (ethanol) polymer and combinations thereof, Therapeutic nanoparticles include about 10-30% polymer (ethyl) glycerin, wherein the therapeutic agent is 1 - (4 - [4 - (dimethylamine) piperidin-1-il] carbonil) - 3 - [4 - (4,6-dimorfolin-4-il-1,3,5-triazin-2-il) phenyl] urea or a salt acceptable for one of the drugs. Claim 109: a pharmaceutical component, including a therapeutic nanoparticleThis is rule 1-108 and an acceptable pharmacist 110. Claim 110: the pharmaceutical ingredients of claim 109, including a plurality of therapeutic nanoparticles. 2. Claim 111: claimed pharmaceutical ingredients 109 or 110which also includes a saccharide. Claim 112: The pharmaceutical composition of any of claims 109-111, further comprising a cyclodextrin. Claim 113: The pharmaceutical composition of claims 111 or 112, wherein the saccharide is a disaccharide selected from the group consisting of sucrose, trehalose and one of their mixtures. Claim 119: A process for the preparation of a therapeutic nanoparticle, comprising the steps of: combining a first organic phase with a first aqueous solution to form a second phase； the emulsion of the second phase in order to form an emulsion phase,The latex phase consists of the first polymer, therapeutic agent and a major water binder acid； closing the la
